Genome&Company Logo

Genome&Company

Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.

314130 | KO

Overview

Corporate Details

ISIN(s):
KR7314130006
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 7층, 8층, 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genome & Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's core research and development programs are centered on microbiome-based pharmaceuticals, novel immune checkpoint inhibitors, and antibody-drug conjugates (ADCs). Its primary therapeutic area is immuno-oncology, aiming to develop new treatments for various cancers. Genome & Company utilizes its proprietary drug discovery platform to advance its pipeline through clinical trials and strategic partnerships, including the out-licensing of its drug candidates to global pharmaceutical firms.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-21 00:00
M&A Activity
주요사항보고서(타법인주식및출자증권양도결정)
Korean 20.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 68.4 KB
2025-08-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.3 KB
2025-07-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 77.8 KB
2025-07-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 68.8 KB
2025-07-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 80.9 KB
2025-07-10 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.7 KB
2025-07-02 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 186.7 KB
2025-07-02 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 177.1 KB
2025-06-04 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 8.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.9 KB
2025-05-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.6 KB

Automate Your Workflow. Get a real-time feed of all Genome&Company filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genome&Company

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genome&Company via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.